The estimated Net Worth of Frank X Leonard is at least 14.3 百万$ dollars as of 1 March 2024. Mr. Leonard owns over 2,519 units of NovoCure Ltd stock worth over 2,758,489$ and over the last 4 years he sold NVCR stock worth over 11,492,521$. In addition, he makes 0$ as Chief Development Officer at NovoCure Ltd.
Frank has made over 24 trades of the NovoCure Ltd stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 2,519 units of NVCR stock worth 40,354$ on 1 March 2024.
The largest trade he's ever made was selling 39,507 units of NovoCure Ltd stock on 5 January 2023 worth over 4,434,661$. On average, Frank trades about 4,524 units every 38 days since 2020. As of 1 March 2024 he still owns at least 160,098 units of NovoCure Ltd stock.
You can see the complete history of Mr. Leonard stock trades at the bottom of the page.
Frank Leonard has been appointed as Chief Development Officer of the Company effective 9/1/2020. Mr. Leonard joined Novocure in 2010 to help prepare the company for the commercial launch of Optune®. In this role, he established Novocure's health policy and business development groups, and additionally led various finance functions. Prior to joining Novocure, Mr. Leonard was a venture capital investor focused on high-impact medical technologies. Mr. Leonard holds an A.B. from Harvard and an M.A. from the London School of Economics and Political Science.
Frank's mailing address filed with the SEC is C/O NOVOCURE INC., 1550 LIBERTY RIDGE DRIVE, SUITE 115, WAYNE, PA, 19087.
Over the last 9 years, insiders at NovoCure Ltd have traded over 237,132,855$ worth of NovoCure Ltd stock and bought 164,174 units worth 2,198,429$ . The most active insiders traders include Asaf Danziger、William Fwfd Ventures Fund ...、Michael J. Ambrogi. On average, NovoCure Ltd executives and independent directors trade stock every 7 days with the average trade being worth of 853,350$. The most recent stock trade was executed by Ashley Cordova on 2 August 2024, trading 688 units of NVCR stock currently worth 13,856$.
we are a commercial-stage oncology company developing a novel, proprietary therapy called tumor treating fields, or ttfields, for the treatment of solid tumor cancers. we count on the contributions of our talented team members who are committed to improving the lives of cancer patients. here at novocure, cancer patients and their families are – and have always been – at the core of our mission. we expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. we seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. we offer employment opportunities in the u.s., europe and asia.
NovoCure Ltd executives and other stock owners filed with the SEC include: